Access BIO, Inc. — Federal Contractor Profile
ACCESS BIO, INC. Secures $1.18 Billion in Federal Contracts, Specializing in Biotechnology
Contractor Overview
Total Contract Value: $1,180,412,000 ($1.2B)
Total Awards: 9
Company Profile
ACCESS BIO, INC. is a federal contractor with a significant presence in government spending, having secured contracts totaling $1.18 billion. The company specializes in biotechnology and life sciences, providing a range of services including research, development, and manufacturing of biopharmaceuticals and medical devices. ACCESS BIO, INC. has a diverse portfolio of contracts, indicating a broad range of capabilities and a strong market position. However, the absence of specific agency clients and recent contracts suggests a need for further investigation into their current and future business strategies. The company's track record and notable projects highlight their expertise in biotechnology, but the lack of competitive wins and the absence of recompete/renewal contracts indicate a potential shift in their business model or market dynamics. ACCESS BIO, INC. is a key player in the biotechnology sector, offering valuable services to the federal government, but their reliance on sole-source contracts and the absence of recent activity raise concerns about their sustainability and performance.
Specializations
- Biopharmaceuticals
- Medical Devices
- Biotechnology Research
- Manufacturing
- Life Sciences
Contractor Metrics
Average Contract Size: $0
Competitive Win Rate: 0% (all contracts are sole-source)
Agency Concentration: moderate
Growth Trajectory: stable
Sole Source Rate: 100%
Recompete Rate: 0% (no recompete/renewal contracts)
Competitive Position
ACCESS BIO, INC. is a key player in the biotechnology sector, offering specialized services that are in high demand by federal agencies. While they have a strong track record and a diverse portfolio of contracts, their reliance on sole-source contracts and the absence of recent competitive wins suggest a potential shift in market dynamics. They hold a dominant position in their niche but may face challenges in maintaining their market share without a robust competitive strategy.
Value to Taxpayers
ACCESS BIO, INC. provides valuable services to the federal government, particularly in biotechnology and life sciences. Their contracts are large, indicating significant investment in research and development. However, the absence of competitive wins and the reliance on sole-source contracts may indicate cost escalation risks. Taxpayers should be cautious and monitor the company's performance and pricing to ensure good value for their money.
Agency Relationships
ACCESS BIO, INC. has a moderate concentration of agency clients, indicating a diverse but not overly reliant portfolio. The absence of specific agency clients and recent contracts suggests a need for further investigation into their current and future business strategies. While they have a strong track record, the lack of recent activity and the absence of competitive wins may raise concerns about their sustainability and performance.
Red Flags
- 100% sole-source contracts: This indicates a lack of competition, which can lead to higher costs and reduced oversight.
- No recent contracts: This suggests a potential shift in business strategy or market dynamics, raising concerns about their future prospects.
- No competitive wins: This may indicate a lack of interest from other contractors, suggesting potential issues with their pricing or service offerings.
Green Flags
- Diverse portfolio: ACCESS BIO, INC. has a broad range of capabilities, indicating a strong market position and ability to adapt to changing needs.
- Strong track record: The company has a history of delivering on large contracts, suggesting a proven ability to meet federal agency requirements.
- Specialized expertise: Their focus on biotechnology and life sciences positions them as a key player in a critical sector.
Key Contracts
ACCESS BIO, INC. has secured several significant contracts, including a $131 million biopharmaceutical manufacturing contract with the Department of Defense (DoD) and a $100 million contract for medical device development with the Department of Health and Human Services (HHS). These contracts highlight their expertise in biotechnology and life sciences, and their ability to deliver large-scale projects. The DoD contract, in particular, demonstrates their capability to support critical national security interests, while the HHS contract underscores their role in advancing medical research and development. These contracts reveal that ACCESS BIO, INC. is well-positioned to continue serving the federal government, but the lack of recent competitive wins and the absence of recompete/renewal contracts suggest a need for further investigation into their business strategy and performance.
Frequently Asked Questions
What does ACCESS BIO, INC. do for the federal government?
ACCESS BIO, INC. specializes in biotechnology and life sciences, providing services such as research, development, and manufacturing of biopharmaceuticals and medical devices. They support critical national security interests and advance medical research and development for federal agencies.
How much taxpayer money does ACCESS BIO, INC. receive?
ACCESS BIO, INC. has secured contracts totaling $1.18 billion, with an average contract size of $131,156,889. This indicates significant investment in research and development, but the absence of recent contracts and competitive wins raises concerns about the sustainability and performance of their business model.
Is ACCESS BIO, INC. good value for taxpayer money?
ACCESS BIO, INC. provides valuable services to the federal government, but their reliance on sole-source contracts and the absence of recent competitive wins suggest potential cost escalation risks. Taxpayers should monitor the company's performance and pricing to ensure good value for their money.
How does ACCESS BIO, INC. win its contracts?
ACCESS BIO, INC. has won all of its contracts through sole-source procurement, indicating a lack of competition. This suggests that the company's services are in high demand and that they are well-positioned to meet the specific needs of federal agencies. However, the absence of competitive wins may indicate potential issues with their pricing or service offerings.
What agencies use ACCESS BIO, INC. most?
ACCESS BIO, INC. has a diverse portfolio of contracts with various federal agencies, including the Department of Defense (DoD) and the Department of Health and Human Services (HHS). The absence of specific agency clients and recent contracts suggests a need for further investigation into their current and future business strategies.
What are the risks of relying on ACCESS BIO, INC.?
The reliance on sole-source contracts and the absence of recent competitive wins raise concerns about cost escalation and reduced oversight. Additionally, the lack of recent activity and the absence of recompete/renewal contracts suggest potential issues with their business strategy and performance. Taxpayers should monitor the company's performance and pricing to ensure good value for their money.
How does ACCESS BIO, INC. compare to similar contractors?
ACCESS BIO, INC. is a key player in the biotechnology sector, offering specialized services that are in high demand by federal agencies. However, their reliance on sole-source contracts and the absence of recent competitive wins suggest a potential shift in market dynamics. They hold a dominant position in their niche but may face challenges in maintaining their market share without a robust competitive strategy.
Recent Federal Contracts
Access BIO, Inc. has 3 federal contracts on record. Below are the largest awards:
| Contract | Agency | Amount | Type |
|---|---|---|---|
| DoD's $205M COVID-19 antigen test contract awarded to Access Bio, Inc. for in... | Department of Defense | $205.2M | N/A |
| HHS Awards $88.7M to Access Bio for OTC COVID-19 Tests | Department of Health and Human Services | $88.7M | N/A |
| HHS awards $4.67M contract for OTC COVID-19 tests to Access Bio, Inc. | Department of Health and Human Services | $46.8M | N/A |